The Latest Breaking News from Merck

The Dow Jones Industrial Average fell Friday, as the price of Bitcoin tumbled below $22,000. BBBY stock crashed after Ryan Cohen cashed out.

The Dow Jones Industrial Average fell Thursday after key economic data. BBBY stock dived after RC Ventures disclosed a plan to sell shares.

Seagen lost a royalty battle Friday, but SGEN stock jumped on the potential the rumored Merck acquisition could be looming.

The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug Application (NDA) for elacestrant for patients with ER+/HER2- advanced or metastatic breast cancer. The agency has granted Priority Review designation and assigned a target action date of February 17, 2023. Radius Health…

Here's a roundup of top developments in the biotech space over the last 24 hours:

Merck & Co.’s Januvia, a popular diabetes drug, was found to be contaminated with a potential carcinogen.

The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline B

The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ:MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. MediWound shares traded in a range of $1.6 to $1.76 on a day…

Here's a roundup of top developments in the biotech space over the last 24 hours: